BTIG ups Verastem to buy from neutral; PT $8


BTIG upgraded Verastem (NASDAQ:VSTM) to “buy” from “neutral” with a new price target of $8, citing a breakthrough designation from the FDA for its KRAS-focused combination therapy of VS-6766 with defactinib for all patients with recurrent low-grade serious ovarian cancer regardless of KRAS status, after one or more prior lines of therapy. 

Shares of Verastem were quoted at $3.65, up 45 cents, at mid-day on May 24.

KRAS is one of a group of genes involved in the epidermal growth factor receptor pathway.

Analyst Robert Hazlett writes that the FDA decision follows data from the

company’s Phase 1/2 FRAME study, which most recently showed an objective response rate (ORR) of 52% (11/21 response evaluable patients), 70% ORR with KRAS mutant tumors (7/10 response evaluable patients), and 44% ORR with KRAS wild-type tumors (4/9 response evaluable patients). 

“With this early but meaningful regulatory validation de-risking the program, we upgrade Verastem shares to “buy,” he said. 

Mr. Hazlett said Verastem recently initiated a Phase 2 registration-directed trial of VS-6766 with defactinib for recurrent low-grade serious ovarian cancer and an adaptive Phase 2 trial investigating VS-6766 alone and in combination with defactinib in KRAS mutant non-small cell lung cancer (NSCLC) patients. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.